ClinicalTrials.gg
Active, not recruitingNCT05540860Updated Nov 12, 2025

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

A Phase 2 interventional study of Sevasemten Dose 1 and Sevasemten Dose 2 in Duchenne Muscular Dystrophy, sponsored by Edgewise Therapeutics, Inc.. Active, not recruiting at 14 sites in United States. Open to male participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Edgewise Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
4 Years to 9 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
40th of 171
76 · median 25
Started
2022
with 14 others
Phase 2
57 of 232
4 open now
Primary completion
2027-01
later than 16 of 59 live
Registered
185th of 232
by date
Lead sponsor
6 of 232
Edgewise Therapeutics, Inc.

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 40th largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2022, is one of 57 in phase 2, reaches primary completion later than 16 of the 59 other live ones, and was the 185th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 9 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.

Read the detailed description

This is a 2-part, multi-center, Phase 2 study to evaluate the effect of sevasemten (EDG-5506) on safety, pharmacokinetics and biomarkers of muscle damage in approximately 72 children with DMD treated with oral, once-daily sevasemten for up to 48 months. This study will have up to a 4-week Screening period, a 12-week randomized, double-blind, placebo controlled treatment period (Part A), up to a 196-week open-label extension period (Part B), and a 2-week follow up period.

Approximately 72 participants aged 4 to 9 years inclusive will be randomized to sevasemten or placebo in a 2:1 ratio. Five dose cohorts (C1, C2, C3, C4 and C5) of approximately 9 participants each will be enrolled sequentially. Approximately 18 total additional participants may be added across Cohorts 2, 3, or 4.

An additional cohort, Cohort 2NS, to include participants (aged 4 to 7 years inclusive) not currently treated with corticosteroids, will enroll approximately 9 participants after Cohort 2 safety review and in parallel with the additional cohorts.

After review of emerging data, the protocol was amended so all dose cohorts receive the same dose in Part B.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Common Inclusion Criteria:

  1. A documented mutation on the DMD gene and phenotype consistent with Duchenne muscular dystrophy.
  2. Able to complete the stand from supine in ≤ 10 seconds and able to perform the 4-stair climb in \< 10 seconds at the Screening visit.
  3. Body weight greater than or equal to 15 kg at the Screening visit.

For Cohorts 1, 2, 3, 4 and 5:

Aged 4-9 years on a stable dose of for a minimum of 6 months prior to the Baseline visit.

For Cohort 2 Non-Steroid (Cohort 2NS):

Aged 4-7 years not on corticosteroids within 6 months prior to the Baseline visit.

Key Common Exclusion Criteria:

  1. Medical history or physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood testing.
  2. A forced vital capacity \< 60% predicted at the Screening visit for those participants who are > 8 years old at Screening.
  3. A cardiac echocardiography showing left ventricular ejection \< 45% at the Screening visit.
  4. Receipt of an drug within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
  5. Receipt of a stable dose of an approved exon-skipping therapy with a treatment duration of less than 1 year prior to the Screening visit.

For Cohort 2 Non-Steroid (Cohort 2NS):

Receipt of oral corticosteroids for the treatment of Duchenne muscular dystrophy in the previous 6 months. Participants will not be tapered off steroids for the purpose of this study and oral corticosteroids for the treatment of Duchenne muscular dystrophy may be initiated after the Week 16 visit.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 1 · Drug: Placebo

  • Experimental
    Cohort 2

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 2 · Drug: Placebo

  • Experimental
    Cohort 3

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 3 · Drug: Placebo

  • Experimental
    Cohort 4

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 4 · Drug: Placebo

  • Experimental
    Cohort 5

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 5 · Drug: Placebo

  • Experimental
    Cohort 2NS

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 2 · Drug: Placebo

Interventions

  • DrugSevasemten Dose 1

    Sevasemten is administered orally once per day

  • DrugSevasemten Dose 2

    Sevasemten is administered orally once per day

  • DrugSevasemten Dose 3

    Sevasemten is administered orally once per day

  • DrugSevasemten Dose 4

    Sevasemten is administered orally once per day

  • DrugSevasemten Dose 5

    Sevasemten is administered orally once per day

  • DrugPlacebo

    Placebo is administered orally once per day

06

What researchers measure

Primary outcomes

  1. Number of adverse events during treatment with sevasemten or placebo

    All participants

    Time frame: 48 months

  2. Severity of adverse events during treatment with sevasemten or placebo

    All participants

    Time frame: 48 months

Secondary outcomes

  1. Incidence of laboratory test-related treatment emergent adverse events

    All participants

    Time frame: 48 months

  2. Pharmacokinetics as measured by steady state plasma concentration

    All participants

    Time frame: 48 months

  3. Change from Baseline in serum creatinine kinase

    All participants

    Time frame: 12 weeks

  4. Change from Baseline in fast skeletal muscle troponin I

    All participants

    Time frame: 12 weeks

07

Study locations

14 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jan 2027, 51 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 51 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 15, 2022
StartActual
Oct 24, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05540860
Lead sponsor
Edgewise Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 15, 2022
Start date
Oct 24, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion